Drugs / AZD3161
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01240148 | Dec 2010 → Mar 2011 | neuropathy, painful | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01240148 ↗ |
| Action | Inhibit | “Sodium channel protein type IX alpha subunit blocker” CHEMBL3545208 ↗ |
| Route | Other | “intradermal injection” NCT01240148 ↗ |
| Target | SCN9A | “Sodium channel protein type IX alpha subunit blocker” CHEMBL3545208 ↗ |